Astria Therapeutics
ATXS
ATXS was delisted on the 22nd of January, 2026.
80 hedge funds and large institutions have $286M invested in Astria Therapeutics in 2023 Q4 according to their latest regulatory filings, with 20 funds opening new positions, 35 increasing their positions, 16 reducing their positions, and 8 closing their positions.
188% more call options, than puts
Call options by funds: $345K | Put options by funds: $120K
150% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 8
119% more repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 16
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
67% more capital invested
Capital invested by funds: $171M → $286M (+$114M)
20.62% more ownership
Funds ownership: 81.96% → 102.58% (+21%)
18% more funds holding
Funds holding: 68 → 80 (+12)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VA
VR Adviser
New York
|
+$17.8M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$12.4M |
| 3 |
PA
Perceptive Advisors
New York
|
+$10M |
| 4 |
FFM
Fairmount Funds Management
West Conshohocken,
Pennsylvania
|
+$9.14M |
| 5 |
AC
Armistice Capital
New York
|
+$8.73M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$7.74M |
| 2 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$5.69M |
| 3 |
ACM
Altium Capital Management
New York
|
-$3.41M |
| 4 |
SVCM
Saturn V Capital Management
Austin,
Texas
|
-$1.26M |
| 5 |
PAMP
Polar Asset Management Partners
Toronto,
Ontario, Canada
|
-$1.15M |
ATXS Hedge Fund Activity: Q4 2023 in Review
80 of the 6,860 institutional investors tracked by Wall St. Rank reported a position in Astria Therapeutics (ATXS) for Q4 2023, worth a combined $286M — up 67% from $171M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new ATXS positions and 8 closed out — a net gain of 12 holders — while 35 added to existing stakes and 16 trimmed.
The largest buyer was VR Adviser, opening a new position worth an estimated $17.8M. The largest seller was Deep Track Capital, exiting entirely with an estimated $7.74M sold.
- 80 institutional investors held Astria Therapeutics (ATXS) as of Q4 2023, up from 68 in Q3 2023.
- Funds reported $286M of Astria Therapeutics stock for Q4 2023, up 67% quarter-over-quarter.
- 20 funds opened new Astria Therapeutics positions in Q4 2023 and 8 closed out, a net change of +12 holders.
- The largest Astria Therapeutics buyer in Q4 2023 was VR Adviser, an estimated $17.8M added.
- The largest Astria Therapeutics seller in Q4 2023 was Deep Track Capital, an estimated $7.74M sold.
Based on aggregated 13F filings for Q4 2023.